File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Future prevention and treatment of chronic hepatitis B infection

TitleFuture prevention and treatment of chronic hepatitis B infection
Authors
Seto, WKFung, JYuen, MFLai, CL
Keywordsbesifovir
FG-3019
HELIPSAV
interferon-λ
REP 9AC
vaccination
Issue Date2012
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.com
Citation
Journal of Clinical Gastroenterology, 2012, v. 46 n. 9, p. 725-734 How to Cite?
DOI: http://dx.doi.org/10.1097/MCG.0b013e3182610191
AbstractVaccination for hepatitis B virus (HBV) infection and treatment for chronic hepatitis B, while effective for primary prevention and control of the disease, still have their limitations. Global coverage of HBV immunization needs improvement. Several patient populations are noted to have suboptimal seroprotective rates after HBV vaccination. There are currently several potential new vaccines undergoing animal and human studies, most notably vaccines containing immunostimulatory DNA sequences. Long-term nucleoside analogue therapy is necessary in achieving permanent virologic suppression. Potential new treatments explore new mechanisms of action, including the inhibition of hepatitis B surface antigen release, targeting antifibrotic mechanism, and immunomodulation through novel interferons and therapeutic vaccines. The clinical application of potential new vaccines and therapies would enhance the prevention of HBV infection and treatment of chronic hepatitis B. © 2012 by Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/164364
ISSN
0192-0790
2023 Impact Factor: 2.8
2023 SCImago Journal Rankings: 0.906
ISI Accession Number ID
WOS:000308703100005
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorFung, Jen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2012-09-20T07:58:12Z-
dc.date.available2012-09-20T07:58:12Z-
dc.date.issued2012en_HK
dc.identifier.citationJournal of Clinical Gastroenterology, 2012, v. 46 n. 9, p. 725-734en_HK
dc.identifier.issn0192-0790en_HK
dc.identifier.urihttp://hdl.handle.net/10722/164364-
dc.description.abstractVaccination for hepatitis B virus (HBV) infection and treatment for chronic hepatitis B, while effective for primary prevention and control of the disease, still have their limitations. Global coverage of HBV immunization needs improvement. Several patient populations are noted to have suboptimal seroprotective rates after HBV vaccination. There are currently several potential new vaccines undergoing animal and human studies, most notably vaccines containing immunostimulatory DNA sequences. Long-term nucleoside analogue therapy is necessary in achieving permanent virologic suppression. Potential new treatments explore new mechanisms of action, including the inhibition of hepatitis B surface antigen release, targeting antifibrotic mechanism, and immunomodulation through novel interferons and therapeutic vaccines. The clinical application of potential new vaccines and therapies would enhance the prevention of HBV infection and treatment of chronic hepatitis B. © 2012 by Lippincott Williams & Wilkins.en_HK
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.comen_HK
dc.relation.ispartofJournal of Clinical Gastroenterologyen_HK
dc.rightsThis is a non-final version of an article published in final form in Journal of Clinical Gastroenterology, 2012, v. 46 n. 9, p. 725-734-
dc.subjectbesifoviren_HK
dc.subjectFG-3019en_HK
dc.subjectHELIPSAVen_HK
dc.subjectinterferon-λen_HK
dc.subjectREP 9ACen_HK
dc.subjectvaccinationen_HK
dc.titleFuture prevention and treatment of chronic hepatitis B infectionen_HK
dc.typeArticleen_HK
dc.identifier.emailSeto, WK: wkseto2@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authoritySeto, WK=rp01659en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturepostprint-
dc.identifier.doi10.1097/MCG.0b013e3182610191en_HK
dc.identifier.pmid22914347-
dc.identifier.scopuseid_2-s2.0-84866240582en_HK
dc.identifier.hkuros210584en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84866240582&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume46en_HK
dc.identifier.issue9en_HK
dc.identifier.spage725en_HK
dc.identifier.epage734en_HK
dc.identifier.isiWOS:000308703100005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridSeto, WK=23390675900en_HK
dc.identifier.scopusauthoridFung, J=55340028900en_HK
dc.identifier.scopusauthoridYuen, MF=55340078900en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.issnl0192-0790-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats